Compare Aurobindo Pharma with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs DIVIS LABORATORIES - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA DIVIS LABORATORIES AUROBINDO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 16.8 49.9 33.6% View Chart
P/BV x 3.6 13.4 27.2% View Chart
Dividend Yield % 0.3 0.5 63.3%  

Financials

 AUROBINDO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
DIVIS LABORATORIES
Mar-19
AUROBINDO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs8301,639 50.6%   
Low Rs5271,115 47.3%   
Sales per share (Unadj.) Rs333.9186.3 179.2%  
Earnings per share (Unadj.) Rs40.451.0 79.2%  
Cash flow per share (Unadj.) Rs51.857.3 90.3%  
Dividends per share (Unadj.) Rs2.5016.00 15.6%  
Dividend yield (eoy) %0.41.2 31.7%  
Book value per share (Unadj.) Rs237.1261.8 90.6%  
Shares outstanding (eoy) m585.91265.47 220.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.07.4 27.5%   
Avg P/E ratio x16.827.0 62.2%  
P/CF ratio (eoy) x13.124.0 54.6%  
Price / Book Value ratio x2.95.3 54.4%  
Dividend payout %6.231.4 19.7%   
Avg Mkt Cap Rs m397,569365,592 108.7%   
No. of employees `00017.911.8 150.7%   
Total wages/salary Rs m25,8495,423 476.7%   
Avg. sales/employee Rs Th10,956.94,175.1 262.4%   
Avg. wages/employee Rs Th1,447.7457.7 316.3%   
Avg. net profit/employee Rs Th1,324.31,141.8 116.0%   
INCOME DATA
Net Sales Rs m195,63649,463 395.5%  
Other income Rs m1,5531,556 99.8%   
Total revenues Rs m197,18951,019 386.5%   
Gross profit Rs m39,51918,718 211.1%  
Depreciation Rs m6,6801,689 395.5%   
Interest Rs m2,62635 7,502.9%   
Profit before tax Rs m31,76718,551 171.2%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,2695,023 144.7%   
Profit after tax Rs m23,64513,527 174.8%  
Gross profit margin %20.237.8 53.4%  
Effective tax rate %22.927.1 84.5%   
Net profit margin %12.127.3 44.2%  
BALANCE SHEET DATA
Current assets Rs m153,64546,501 330.4%   
Current liabilities Rs m120,4298,468 1,422.2%   
Net working cap to sales %17.076.9 22.1%  
Current ratio x1.35.5 23.2%  
Inventory Days Days135131 103.4%  
Debtors Days Days6486 74.2%  
Net fixed assets Rs m103,90925,797 402.8%   
Share capital Rs m586531 110.4%   
"Free" reserves Rs m138,32268,962 200.6%   
Net worth Rs m138,90869,493 199.9%   
Long term debt Rs m1,8000-   
Total assets Rs m264,54480,383 329.1%  
Interest coverage x13.1531.0 2.5%   
Debt to equity ratio x00-  
Sales to assets ratio x0.70.6 120.2%   
Return on assets %9.916.9 58.9%  
Return on equity %17.019.5 87.4%  
Return on capital %23.826.7 89.1%  
Exports to sales %49.60-   
Imports to sales %18.824.6 76.2%   
Exports (fob) Rs m97,091NA-   
Imports (cif) Rs m36,74112,187 301.5%   
Fx inflow Rs m97,31641,238 236.0%   
Fx outflow Rs m40,58912,405 327.2%   
Net fx Rs m56,72728,833 196.7%   
CASH FLOW
From Operations Rs m16,2209,543 170.0%  
From Investments Rs m-28,768-6,854 419.7%  
From Financial Activity Rs m19,191-2,459 -780.3%  
Net Cashflow Rs m6,656230 2,899.1%  

Share Holding

Indian Promoters % 54.1 52.0 104.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 11.8 67.4%  
FIIs % 27.7 19.0 145.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 17.2 59.3%  
Shareholders   69,601 31,796 218.9%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  ALEMBIC  ALEMBIC PHARMA  CADILA HEALTHCARE  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS